Abstract: Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.

Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.

Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s)?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?.Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.

Abstract: The present invention discloses modified Streptococcus pneumoniae pneumolysin proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified pneumolysin protein and an antigen (for example a Streptococcus pneumoniae saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified pneumolysin protein.

Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.

Abstract: Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.

Abstract: Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.

Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.

Abstract: A process for the production of a glycoconjugate by N-glycosylation of a protein or peptide comprising the sequence D/E-X—N—X—S/T, wherein each X is the same or different and is any natural amino acid other than proline, wherein the process comprises reacting the protein or peptide with a polyisoprenyl pyrophosphate of formula (I), or a salt thereof, in the presence of PglB: (I) to produce the glycoconjugate comprising the protein or peptide having a saccharide [SI] linked to the asparagine in the sequence D/E-X—N—X—S/T. Polyisoprenylpyrophosphates used as substrates in the biocatalytic process are also provided, as well as certain glycoconjugates.

Abstract: Described herein are methods and systems for O-glycosylating proteins in vivo or in vitro in any prokaryotic organism. In these methods and systems, DNA comprising a gene that produces a PglL-like oligosaccharyltransferase and DNA comprising a gene that produces a protein to be O-glycosylated are used. The PglL-like oligosaccharyltransferase facilitates the covalent attachment of the glycan to the protein to produce the O-glycosylated protein. The methods and systems described herein provide an approach for the design and production of new vaccines and therapeutic agents for the treatment of various diseases.

Abstract: Prokaryotic cells proficient to produce glycoconjugates in vivo are provided herein, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.

Abstract: Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions.

Abstract: Described herein are methods and systems for O-glycosylating proteins in vivo or in vitro in any prokaryotic organism. In these methods and systems, DNA comprising a gene that produces a PglL-like oligosaccharyltransferase and DNA comprising a gene that produces a protein to be O-glycosylated are used. The PglL-like oligosaccharyltransferase facilitates the covalent attachment of the glycan to the protein to produce the O-glycosylated protein. The methods and systems described herein provide an approach for the design and production of new vaccines and therapeutic agents for the treatment of various diseases.